Endothelial epidermal growth factor receptor is of minor importance for vascular and renal function and obesity-induced dysfunction in mice.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 03 2021
31 03 2021
Historique:
received:
23
10
2020
accepted:
16
03
2021
entrez:
1
4
2021
pubmed:
2
4
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Vascular EGF receptors (EGFR) influence function and structure of arterial vessels. In genetic mouse models we described the role of vascular smooth muscle (VSMC) EGFR for proper physiological function and structure as well as for pathophysiological alterations by obesity or angiotensin II. As the importance of endothelial (EC) EGFR in vivo is unknown, we analyzed the impact of EC-EGFR knockout in a conditional mouse model on vascular and renal function under control condition as well as in obesity and in comparison to VSMC-KO. Heart and lung weight, blood pressure and aortic transcriptome (determined by RNA-seq) were not affected by EC-EGFR-KO. Aortic reactivity to α1-adrenergic stimulation was not affected by EC-EGFR-KO contrary to VSMC-EGFR-KO. Endothelial-induced relaxation was reduced in abdominal aorta of EC-EGFR-KO animals, whereas it was enhanced in VSMC-EGFR-KO animals. Mesenteric arteries of EC-EGFR-KO animals showed enhanced sensitivity to α1-adrenergic stimulation, whereas endothelial-induced relaxation and vessel morphology were not affected. Renal weight, histomorphology, function (albumin excretion, serum creatinine, fractional water excretion) or transcriptome were not affected by EC-EGFR-KO, likewise in VSMC-EGFR-KO. High fat diet (HFD) over 18 weeks induced arterial wall thickening, renal weight increase, creatininemia, renal and aortic transcriptome alterations with a similar pattern in EC-EGFR-WT and EC-EGFR-KO animals by contrast to the previously reported impact of VSMC-EGFR-KO. HFD induced endothelial dysfunction in abdominal aortae of EC-EGFR-WT, which was not additive to the EC-EGFR-KO-induced endothelial dysfunction. As shown before, VSMC-EGFR-KO prevented HFD-induced endothelial dysfunction. HFD-induced albuminuria was less pronounced in EC-EGFR-KO animals and abrogated in VSMC-EGFR-KO animals. Our results indicate that EC-EGFR, in comparison to VSMC-EGFR, is of minor and opposite importance for basal renovascular function as well as for high fat diet-induced vascular remodeling and renal end organ damage.
Identifiants
pubmed: 33790318
doi: 10.1038/s41598-021-86587-3
pii: 10.1038/s41598-021-86587-3
pmc: PMC8012653
doi:
Substances chimiques
EGFR protein, mouse
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7269Références
Nat Protoc. 2009;4(8):1184-91
pubmed: 19617889
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Clin Sci (Lond). 2016 Jan;130(1):19-33
pubmed: 26438881
Vascul Pharmacol. 2009 Oct;51(4):236-45
pubmed: 19577003
Int J Mol Sci. 2013 Oct 15;14(10):20597-613
pubmed: 24132149
Dev Biol. 2001 Feb 15;230(2):230-42
pubmed: 11161575
Hypertension. 2013 Feb;61(2):333-40
pubmed: 23248150
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Curr Opin Cell Biol. 2007 Apr;19(2):124-34
pubmed: 17314037
Circ Res. 1977 Jul;41(1):19-26
pubmed: 862138
J Drug Target. 2015;23(6):506-18
pubmed: 26114862
Diabetes. 2016 Jan;65(1):25-33
pubmed: 26696638
Sci Rep. 2019 Jan 18;9(1):204
pubmed: 30659241
Diabetes. 2008 Jun;57(6):1629-37
pubmed: 18319304
Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1643-52
pubmed: 21512163
Arterioscler Thromb Vasc Biol. 2018 Nov;38(11):2550-2561
pubmed: 30354251
Diabetologia. 2020 Oct;63(10):2218-2234
pubmed: 32548701
Annu Rev Pharmacol Toxicol. 2016;56:627-53
pubmed: 26566153
Hypertension. 2012 Jul;60(1):20-1
pubmed: 22665129
Cell Mol Life Sci. 2018 Jun;75(12):2241-2256
pubmed: 29282485
Cell Tissue Res. 2003 Jul;313(1):63-70
pubmed: 12827494
J Biol Chem. 2015 Aug 28;290(35):21603-14
pubmed: 26175156
Genome Biol. 2013 Jul 31;14(7):R82
pubmed: 23902802
Cancer Res. 2006 Feb 15;66(4):2173-80
pubmed: 16489018
J Comp Physiol B. 2014 Aug;184(6):763-75
pubmed: 24788387
Br J Pharmacol. 2005 Jul;145(6):829-36
pubmed: 15852031
Acta Physiol (Oxf). 2018 Mar;222(3):
pubmed: 29152859
Hypertension. 2008 Aug;52(2):264-70
pubmed: 18606907
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Nucleic Acids Res. 2016 Jul 8;44(W1):W83-9
pubmed: 27098042
Curr Opin Nephrol Hypertens. 2014 Mar;23(2):113-21
pubmed: 24401788